These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 32163277)

  • 1. Recent Trends in
    Sun IC; Yoon HY; Lim DK; Kim K
    Bioconjug Chem; 2020 Apr; 31(4):1012-1024. PubMed ID: 32163277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
    Wallace PM; Senter PD
    Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):505-12. PubMed ID: 7885077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of prodrugs for enzyme-mediated, tumor-selective therapy.
    Yoon KJ; Potter PM; Danks MK
    Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):107-13. PubMed ID: 15777218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
    Akinboye ES; Brennen WN; Rosen DM; Bakare O; Denmeade SR
    Prostate; 2016 Jun; 76(8):703-14. PubMed ID: 26835873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzymatic rhamnosylation of anticancer drugs by an α-L-rhamnosidase from Alternaria sp. L1 for cancer-targeting and enzyme-activated prodrug therapy.
    Xu L; Liu X; Li Y; Yin Z; Jin L; Lu L; Qu J; Xiao M
    Appl Microbiol Biotechnol; 2019 Oct; 103(19):7997-8008. PubMed ID: 31414160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Glutathione (GSH)-Responsive Near-Infrared (NIR) Theranostic Prodrug for Cancer Therapy and Imaging.
    Kong F; Liang Z; Luan D; Liu X; Xu K; Tang B
    Anal Chem; 2016 Jun; 88(12):6450-6. PubMed ID: 27216623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prodrug applications for targeted cancer therapy.
    Giang I; Boland EL; Poon GM
    AAPS J; 2014 Sep; 16(5):899-913. PubMed ID: 25004822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prodrugs in cancer chemotherapy.
    Connors TA; Knox RJ
    Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme-catalyzed activation of anticancer prodrugs.
    Rooseboom M; Commandeur JN; Vermeulen NP
    Pharmacol Rev; 2004 Mar; 56(1):53-102. PubMed ID: 15001663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.
    Tietze LF; Schmuck K
    Curr Pharm Des; 2011; 17(32):3527-47. PubMed ID: 22074425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folate receptor-mediated enhanced and specific delivery of far-red light-activatable prodrugs of combretastatin A-4 to FR-positive tumor.
    Nkepang G; Bio M; Rajaputra P; Awuah SG; You Y
    Bioconjug Chem; 2014 Dec; 25(12):2175-88. PubMed ID: 25351441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy.
    Hayashi JY; Tamanoi F
    Enzymes; 2017; 42():153-172. PubMed ID: 29054269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent trends in targeted anticancer prodrug and conjugate design.
    Singh Y; Palombo M; Sinko PJ
    Curr Med Chem; 2008; 15(18):1802-26. PubMed ID: 18691040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
    Connors TA
    Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted prodrug approaches for hormone refractory prostate cancer.
    Aloysius H; Hu L
    Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of enzymatically cleavable prodrugs of a potent platinum-containing anticancer agent.
    Ding S; Pickard AJ; Kucera GL; Bierbach U
    Chemistry; 2014 Dec; 20(49):16164-73. PubMed ID: 25303639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in small molecule prodrugs for cancer therapy.
    Wang P; Jin X; Cai J; Chen J; Ji M
    Anticancer Agents Med Chem; 2014 Mar; 14(3):418-39. PubMed ID: 23869777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity mechanism-based prodrugs: glutathione-dependent bioactivation as a strategy for anticancer prodrug design.
    Zhang XY; Elfarra AA
    Expert Opin Drug Discov; 2018 Sep; 13(9):815-824. PubMed ID: 30101640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
    Senter PD; Springer CJ
    Adv Drug Deliv Rev; 2001 Dec; 53(3):247-64. PubMed ID: 11744170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo and in situ tracking cancer chemotherapy by highly photostable NIR fluorescent theranostic prodrug.
    Wu X; Sun X; Guo Z; Tang J; Shen Y; James TD; Tian H; Zhu W
    J Am Chem Soc; 2014 Mar; 136(9):3579-88. PubMed ID: 24524232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.